If you have been reading about tesamorelin and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
The peptide is supplied as a lyophilized powder in single-use vials and is normally kept refrigerated between two and eight degrees Celsius, protected from light. Once dissolved, the solution is handled carefully because peptide bonds and the acyl modification can degrade under warm or alkaline conditions. Vials are inspected for cracks, and the powder is checked for color and uniformity before handling. Temperature excursions during shipping are a frequent reason for quality questions.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from truncated or oxidized forms. Mass spectrometry confirms the expected molecular weight, and peptide mapping after enzymatic digestion verifies the amino acid sequence. Water content is measured because residual moisture affects stability, and tests for aggregates or particulates are standard for injectable peptides. Circular dichroism can indicate whether the molecule has adopted an unexpected secondary structure in solution.
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
The company partnered with Baptist Memorial Health Care to establish a bacteriology centre of excellence (Memphis, Tennessee), with Western Connecticut Health Network to form Constitution Diagnostics Network, and with NYU Health System to form NYU Langone Diagnostics (New York). In 2018, Sonic acquired Pathology Trier (Germany). The company partnered with ProMedica Health System to form ProMedica Pathology Laboratories (Ohio and adjacent states). In 2019, the company acquired Aurora Diagnostics (USA) and sold its interest in GLP systems (Germany). In 2020–2021, Sonic acquired Pathologie Hamburg, a majority stake in Epworth Medical Imaging (Victoria, Australia) and in Harrison.ai's pathology solutions, Canberra Imaging Group, and ProPath (Dallas, Texas). In 2022, Sonic acquired a 19.99% state in Microba Life Sciences Limited - ASX:MAP (Queensland, Australia). Sonic and Microba have agree on a strategic alliance to exclusively deliver Microba's microbiome testing Technology in Germany, the United Kingdom and Belgium as well as a non-exclusive distribution within Sonic's broader network including Australia, Switzerland, the United States and New Zealand.
=== Legal status === Butorphanol is listed under the Single Convention on Narcotic Drugs 1961 and in the United States is a Schedule IV controlled substance with a DEA ACSCN of 9720. The free base conversion ratio of the hydrochloride is 0.69. Butorphanol was originally a Schedule II controlled substance and was later decontrolled at one point.
== Research == (2R,6R)-HNK is under development by the National Institute of Mental Health (NIMH) in the United States for the treatment of depression. As of late 2019, it is in phase I clinical trials for this indication. It is also under development under the developmental code name SPL-801-B by Cybin for depressive disorders.
== Research == Borchers' research centres on the development and application of proteomics and metabolomics technologies, particularly quantitative targeted proteomics for clinical diagnostics. As of July 2026, according to Google Scholar, his publications had been cited more than 33,000 times, with an h-index of 88.
=== Alternative lists in SN/SA === The twelve branched list, though popular, is just one of the many lists of dependently originated dharmas which appear in the early sources. According to Analayo, the alternative lists of dependently arisen phenomena are equally valid "alternative expressions of the same principle". Choong notes that some discourses (SN 12.38-40 and SA 359-361) contain only 11 elements, omitting ignorance and starting out from willing (ceteti). SN 12.39 begins with three synonyms for saṅkhāra, willing, intending (pakappeti) and carrying out (anuseti). It then states that "this becomes an object (arammanam) for the persistence of consciousness (viññanassa-thitiya)" which leads to the appearance of name and form. The standard listing then follows. SN 12.38 (and the parallel at SA 359) contain a much shorter sequence, it begins with willing as above which leads to consciousness, then following after consciousness it states: "there is in the future the becoming of rebirth (punabbhavabhinibbatti)", which leads to "coming-and-going (agatigati)", followed by "decease-and-rebirth (cutupapato)" and following that "there arise in the future birth, ageing-and-death, grief, lamentation, pain, distress, and despair." Another short sequence is found at SN 12. 66 and SA 291 which contain an analysis of dependent origination with just three factors: craving (tanha), basis (upadhi, possibly related to upadana), and suffering (dukkha).
Sources: en.wikipedia.org
=== Therapeutics === There are therapeutics used clinically which can effect the activity of P-type calcium channels. However, the primary target of these therapeutics are not thought to be P-type channels. For example, calcium antagonists, which are used to treat coronary heart disease, hypertension, and cardiac arrhythmia, act by inhibiting L-type or T-type calcium channels. Some of these calcium antagonists include verapamil, diltiazem, amlodipine, benidipine, cilnidipine, nicardipine, and barnidipine. Although their main target is not P-type channels, these calcium antagonists also act to block the function of P-type channels. Moreover, flunarizine is another calcium antagonist which is used to treat migraines. Its main targets are voltage-gated calcium channels and sodium channels. Flunarizine inhibits the P-type channels that are located in the neocortical slices. It works to inhibit the inward flux of calcium. The migraines that it helps to prevent are due to mutations within the "cacna1a" gene of the P-type channel subunit. Also, compounds that block P-type channels are shown to help with seizures. Epileptic seizures are caused by increased neurotransmission, which is partially a result of P-type channels. Compounds such as levetiracetam, lamotrigine, and carbamazepine are known to block the P-type channels, which have helped to decrease the occurrence of seizures.
== Capabilities and departments == A Criminal Investigation Department (CID) was founded in 1923; a Women's Section in 1941, and a Dog Unit in 1945. From 1957, the Police Reserve also had an airborne wing. Prior to the use of motor vehicles, extended rural patrols were carried out on horseback, and right up until the Force was renamed all white male officers were taught equitation as part of their basic traíning. Selected officers were retained in Morris Depot after "passing out" and tasked with training remount horses for future use by recruits and on ceremonial duties. Mounted Escorts were provided for occasions such as the State Opening of Parliament. Generally speaking, the force was the 'Senior Service' and performed ceremonials such as those allocated to the RCMP today. As such, discipline, presentation, and parade drill were of a very high standard. The Support Unit (known as the "Black Boots" due to their footwear) was a Police field force staffed by about 50 white and 1700 (as of 1980) black regular and national servicemen. In the late 1970s a Civilian African Tracking Unit (C.A.T.U.) was added, to relieve the professional trackers in the pursuing of the enemy infiltrators into Rhodesia. Their tracking methods were based on the traditional skills and techniques of the Rhodesian Shangaan tribe. Their formations were called 'sticks', and consisted of a couple of white Rhodesian 'Patrol Officers', or 'Section Officers', and six to eight black Rhodesian trackers.
The family's first home in exile was Wartegg Castle in Rorschach, Switzerland, a property owned by the Bourbon-Parmas. However, the Swiss authorities, worried about the implications of the Habsburgs living near the Austrian border, compelled them to move to the western part of the country. The next month, the Habsburgs moved to Villa Prangins, near Lake Geneva, where they resumed a quiet family life. This abruptly ended in March 1920 when, after a period of instability in Hungary, Miklós Horthy was elected regent. Charles was still technically King (as Charles IV) but Horthy sent an emissary to Prangins advising him not to go to Hungary until the situation had calmed. After the Trianon Treaty Horthy's ambition soon grew. Charles became concerned and requested the help of Colonel Strutt to get him into Hungary. Charles twice attempted to regain control, once in March 1921 and again in October 1921. Both attempts failed, despite Zita's staunch support (she insisted on travelling with him on the final dramatic train journey to Budapest). Charles and Zita temporarily resided at Tata Castle, the home of Count Esterházy, until a suitable permanent exile could be found. Malta was mooted as a possibility, but was declined by Lord Curzon, and French territory was ruled out given the possibility of Zita's brothers intriguing on Charles's behalf. Eventually, the Portuguese island of Madeira was chosen. On 31 October 1921, the former Imperial couple were taken by rail from Tihany to Baja, where the Royal Navy monitor HMS Glowworm was waiting.
In February 2015, the FDA reported about a transmission risk when people undergo a gastroenterology procedure called endoscopic retrograde cholangiopancreatography, where an endoscope enters the mouth, passes the stomach, and ends in the duodenum; if incompletely disinfected, the device can transmit CRE from one patient to another. The FDA's safety communication came a day after the UCLA Health System, Los Angeles, notified more than 100 patients that they may have been infected with CRE during endoscopies between October 2014 and January 2015. The FDA had issued its first notice about the devices in 2009.
Sources: en.wikipedia.org
==== MeSH D06.472.734 – pituitary hormones ==== MeSH D06.472.734.525 – pituitary hormones, anterior MeSH D06.472.734.525.343 – gonadotropins, pituitary MeSH D06.472.734.525.343.288 – follicle stimulating hormone MeSH D06.472.734.525.343.288.500 – follicle stimulating hormone, beta subunit MeSH D06.472.734.525.343.288.625 – follicle stimulating hormone, human MeSH D06.472.734.525.343.288.750 – glycoprotein hormones, alpha subunit MeSH D06.472.734.525.343.463 – luteinizing hormone MeSH D06.472.734.525.343.463.249 – glycoprotein hormones, alpha subunit MeSH D06.472.734.525.343.463.500 – luteinizing hormone, beta subunit MeSH D06.472.734.525.343.583 – menotropins MeSH D06.472.734.525.343.583.500 – urofollitropin MeSH D06.472.734.525.343.773 – prolactin MeSH D06.472.734.525.425 – growth hormone MeSH D06.472.734.525.425.875 – human growth hormone MeSH D06.472.734.525.690 – pro-opiomelanocortin MeSH D06.472.734.525.690.130 – corticotropin MeSH D06.472.734.525.690.130.050 – alpha-msh MeSH D06.472.734.525.690.130.200 – cosyntropin MeSH D06.472.734.525.690.480 – lipotropin MeSH D06.472.734.525.690.583 – melanocyte-stimulating hormones MeSH D06.472.734.525.690.583.050 – alpha-msh MeSH D06.472.734.525.690.583.075 – beta-msh MeSH D06.472.734.525.690.583.115 – gamma-msh MeSH D06.472.734.525.883 – thyrotropin MeSH D06.472.734.525.883.249 – glycoprotein hormones, alpha subunit MeSH D06.472.734.525.883.500 – thyrotropin, beta subunit MeSH D06.472.734.692 – pituitary hormones, posterior MeSH D06.472.734.692.433 – oxytocin MeSH D06.472.734.692.781 – vasopressins MeSH D06.472.734.692.781.100 – argipressin MeSH D06.472.734.692.781.100.250 – deamino arginine vasopressin MeSH D06.472.734.692.781.400 – lypressin MeSH D06.472.734.692.781.400.350 – felypressin MeSH D06.472.734.692.781.700 – ornipressin MeSH D06.472.734.692.881 – vasotocin
By 2015, industry analysts and academic researchers agreed, that the sky-high price of orphan drugs, such as eculizumab, was not related to research, development and manufacturing costs. Their price is arbitrary and they have become more profitable than traditional medicines.Public resources went into understanding the molecular basis of the disease, public resources went into the technology to make antibodies and finally, Alexion, to their credit, kind of picked up the pieces.
Following that investigation and one of their own that faulted the university for failing to act on warnings and protect the campus, the university's faculty senate voted "no confidence" in the president and many other leaders at the university. In 2023, the University of Arizona faced a financial crisis, allegedly "losing track of more than $240 million through accounting errors and flawed financial projections." Subsequent investigative reporting by The Arizona Republic linked much of the crisis to the university's purchase of Ashford University, accusing university administrators of knowing that Ashford was experiencing "a downward enrollment spiral that began years before [the purchase] and dismal graduation and retention rates". In April 2024, the UA chapter of Students for Justice in Palestine joined student protests across the USA against the war in Gaza, during what they called "Israeli Apartheid Week". The encampment was attacked and dispersed by police firing rubber bullets, tear gas and pepper balls. Bystanders and press were also hurt in the police violence. The students were protesting against UA involvement with companies supporting the "genocide and ethnic cleansing in Palestine" and called for divestment.
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
It acts on the growth hormone–releasing hormone receptor, a Gs-coupled receptor found on pituitary somatotroph cells. Activation raises cAMP and prompts pulsatile hormone release.